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Introduction
The clinical significance of cell cannibalism is well defined and 
described in a large number of publications [1,2]. The direction of 
process of cancer developmemt is defined as the tumor invades the 
normal tissue which never occurs in the reverse direction. This suggests 
that the cancer cell strives to achieve the lowest energy level possible. 
Therefore the first law of the development of a full blown cancer can 
be considered as the 2nd Thermodynamic principle [3] that explains, 
describes and drives the invading cancer into normal surrouding tissue.
From the normal living state, under particular conditions such 
as hypoxia, where ATP synthesis is decreased resulting in a switch to 
glycolytic pathways, cancer cells are selected from a fraction of the 
population [4]. Energetically, in the presence of electron transfer, by 
using high energy from respiration, the proliferating state is more stable 
than resting cells where a higher degree of protein stabilization occurs 
such as that needed for maintainance of the cytoskeleton of the cell. It 
was proposed that tumor-promotion might be controlled or modulated 
by small electronic currents originating from reactive oxygen species 
and transported through the cytoskeletal microfilament network of the 
cancer cell [5]. 
Aerobic glycolysis is the main energy producing process in cancer 
cells [6]. Among many other aspects, recently the mitochondria have 
also been regarded as potential targets in the therapy of cancer. Several 
small molecules have been tested to restore their dysfunctional functions 
either by direct or indirect effects [7]. Because of poorly functioning 
mitochondria, the electron transfer component of the respiration cycle 
is inefficient; therefore, cancer cells have smaller Gibbs energy than 
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Abstract
Cancer grows at the expense of the host as a parasite or superparasite following the second law of thermodynamics 
(conservation of energy). When the cancer cell progresses via replication to the special state called “spheroid”, a new 
phase begins with its intimiate interaction and development of responses from the stroma which together assist in the 
formation of a full blown cancer. Among the processes involved are the development of blood vessels and lymphatic 
channels which are essential for maintenance and further growth of the cancer mass. In this way the condition of 
“parasitism” is completed with simultaneous suppression of the immune response of the host to the histoincompatability 
of the tumor mass. Stroma/parenchyma promotes cancer invasion by feeding cancer cells and inducing immune 
tolerance. The dynamic changes in composition of stroma and biological consequences as feeder of cancer cells and 
immune tolerance can give a perspective for rational drug design in anti-stromal therapy. There are differences between 
normal and cancer cells at subcellular level such as compartmentalzation and structure of cytoskeleton and energy 
distribution (that is low generally, but locally high in normal cells). In cancer cannibalism of normal cells, the growing 
cancer mass is a factor for progression and invasion. 
Cancer cells have been shown to kill normal cells and the products of cell death used for progression of growth of 
the cancer cell. Serum and growth factors produced by tumor stroma also provide the needed nutrients and conditions 
for further tumor growth. Cancer cannot feed off other cancer cells and therefore grow poorly. Probably, although not 
yet proven, the inability of cancer to “parasitise” other cancer cell types is probably due to some kind of competition or 
interference. The tumor is in charge of its own development due to its induction proteinases, lipid mobilization factors 
and angiogenetic factors as well as its ability to negate immune responses of the host response to what is in essence 
a foreign body. 
In our review co-existence of normal and cancer cells in tumor with the growth promoting factors, and the immune 
tolerance mediating factors produced in the stromal and cancer cells/tissues will be discussed with perspective of 
stroma targeted therapy.
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healthy cells. This means, that these cancer cells exists in a metastable 
state [8] and are not able maintain normal cell structure. Therefore, the 
cytoskeleton system is collapsed and dielectric bilayers are formed as a 
lower grade of cellular structure with decreased electron conductivity. 
Consequently, to halt cancer growth, one has to evaluate the process of 
cancer cell development in situ, where the primary tumor is growing 
as well as that of the metastatic cell that is invading surrounding or 
distal tissues [9]. This affords one to suggest that the stroma is formed 
first during long term repeated oxidative stress, a process that is initially 
accompanied with inflammation due to an active immune response to 
the histo-incompatability antigens present on the surfce of the cancer 
cell. If the cancer cell evades the activity of killer T cells (Treg cells) by 
either secreting agents that reduce the response of the Treg cells or the 
immune system for whatever reason is ineffective (immunosuppresed 
states such as HIV/AIDS, pregnancy, transplatation therapy, etc.), the 
formed cancer cells have the opportunity to initiate tumor development. 
Because of the limited capacity of its electron transfer cycle, cancer 
cells are essentially starving cells that require glycolytically useful 
substrates. These substrates are obtained from the killing of normal 
cells by agents secreted by the cancer cell and the products yielded from 
dead normal cells “eaten” (phagocytosed) by the starving cancer cell 
which is digested by the cancer cells lysosomal system. This autophagic 
process of cannibalism keeps the cancer cell alive and thriving and 
is known as cytophagy, i.e., cannibalism of normal cells. This type of 
autophagocytosis results in a parasitic co-existence of tumor cells 
with normal cells and will determine the main pathway of interaction 
between the growing cancer tissue (tumor) and normal tissue where the 
cancer tissue gradually destroys normal tissues. This process obeys the 
scond law of thermodynamics-conservation of energy within a defined 
system. 
The conduction of proteins and oxygen consumption are basically 
different in cancer and healthy tissues primarily due to the faulty 
mitochondrial structure. This difference bestows on the cancer cell an 
advantage over the normal cell that makes up the environment in which 
the cancer cell arose [10-12]. When cancer cells receive support from 
feeder fibroblasts for growth, they multiply independently from the 
ordered structure of tissue by forming a new agressive cell population 
that lives at the expense of normal tissue [8]. We have conducted a 
series of experiments that studied the specific coexistence between 
cancer and normal cells. Our aims were to analyse the various stages of 
tumor development with improving the opportunities of intervention 
for cancer therapy based upon the considerations of population biology 
and co-existance of normal and transformed cells or tissues. First of 
all, it should be noted that separate in vitro cultures which contain 
cancer cells and normal cells, repectively, when serum is omitted from 
the medium, the cancer cells survive for a longer period than do the 
normal cells [13]. When the culture contains a mixture of cancer cells 
and normal cells and serum is omitted, the cancer cells fluorish at the 
expense of dying normal cells [13]. These experiments clearly show that 
the cancer cells survive at the expense of the normal cells which when 
alive or dead, yield products that are ingested by the cancer cell. 
As per the second law of thermodynamics, the developing cancer 
cell seeks a lower energy level for its stability. As this process continues, 
tremendous changes occur where the original status, including structure 
and function, can never be regained. In other words, the process leads 
to an irreversible state which progresses to lower energy levels. This 
lower energy state means that whereas the normal cell requires a much 
more stringent source of nutrients, the transformed cancer cell readily 
survives on cell debris, tissue fluid, fibroblasts and other connective 
tissue cells [14]. The limitation of avaliable nutrients does not affect 
the replication of the cancer cell as it does the normal cell. Whereas 
when insufficient nutrient is provided to the normal cell, receptors on 
the surface of the cell promote an inhibition of replication, the cancer 
cell, lacking these receptors, continues to replicate. The colonisation of 
surrounding tissue and organ just began from tumor spheroid state. 4) 
The Stroma Has a Role in the Invasion of Tumor Cells
Cancer cells invade normal tissue of an organ via different types 
of circulations, namely, the circulatory component that drains the site 
where the cancer cell exists and is not firmly attached to neighbouring 
cells or the lymphatic channels that provide similar drainage [15,16]. 
In the case of the circulatory system, the cancer cell may be taken to 
distal parts of the host’s body. In the case of the lymphatic system, the 
cancer cell will reach the first lymphoid nodules where it is trapped, 
but continues to replicate. Therefore, different types of circulations 
specifically mediate the first steps of spreading and invasion into the 
surrounding tissues. The development of tumor stroma and the role 
of stress in tumor progression have been described in detail by several 
authors. There is a plethora of evidence that the tumor stroma differs 
significantly from that of the respective normal tissue. This is a very 
complex microenvironment, composed of connective tissue cells, blood 
vessels, lymphatics, nerves, smooth muscle elements, fat, lymphoid and 
macrophagic elements embedded in the extracellular matrix niche [17]. 
It is well established that there are dynamic and mutual interactions 
between the tumoral cells (e.g. tumor parenchyma) and the stroma, 
and recently, this concept provides the basis for novel treatment 
strategies by considering the opportunities given by the second law 
of thermodynamics [18]. The main components of tumor stroma are 
cancer cells, fibroblasts and immune cells. The biological role of stroma/
parenchyma is feeding the cancer cells building a micro-environment 
for tumor and an interface between host healthy tissues and tumorous 
tissues [17].
Another important cell population in the tumor stroma is the Cancer 
Associated Fibroblast (CAF) that is generated by transforming growth 
factor β1 (TGF-β1). They can produce a variety of cytokines, growth 
factors and ECM proteins in a paracrine manner that further alter the 
microenvironment of the cancer. CAFs, however, have a Janus-face, 
because they may promote tumor growth by enhancing angiogenesis 
and activating the endothelial cells, but they can also exert a tumor-
suppressing effect [22]. Based on parenchyma protein production, the 
cancer associated fibroblast can determine the biophysical properties 
of the matrix favoring again the spreading of the cancer cell [23]. The 
main components and possible targets for intervention localised at the 
The structure of the Extracelluar Matrix (ECM) or tumorous 
parenchyma may determine the degree of resistance the moving cell 
encounters. The malignant cells secreting various soluble factors that 
may remodel the ECM through collagen crosslinking, and tissue 
rigidity can potentially facilitate the directed cell migration. Tumoral 
chemotactic factors may trigger the monocyte → Tumor Associated 
Macrophage (TAM) transformation, and these cells are regarded 
as the major stromal cells responsible for the migration, invasion 
and metastasis formation. These cells are usually accumulated in the 
hypoxic areas of the cancer, and produce several pro-angiogenic factors 
[19]. In addition to TAM production, factors released from the tumor 
cells (interleukins, growth factors) stimulate TAMs to secrete Matrix 
Metalloproteases (MMPs) and other ECM degrading proteases which 
further enhance the invasiveness of the cancer cells [20,21]. Cancer 
cells can change their stroma by cell to cell contacts during tumor 
growth and are capable of modifying the invasiveness and metastasis 
formation of the tumor.
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border (interfase) between “tumor –normal tissue” [24] are: 1. glycolysis 
[6], 2. lipid mobilization factor [25] and 3. proteolysis inducing factor at 
the microenvironment of the tumor-host interface [26].
The Stromal Cells as Possible Targets of Therapy
The stroma and parenchyma containing the various cells and ECM 
can be considered as a new therapeutic target having multiple sub-
targets essential for tumor growth and the immunosuppressive property 
of the cancer cell. Several inhibitors of matrix metalloproteases needed 
for cancer growth, have been shown to inhibit tumor cell growth 
[20,21]. When therapeutic approach co-targets parenchymal, stromal 
cells, the ECM and cytokine elements, a good antitumor effect would be 
achieved. Experimental conditions provide the opportunity to exploit 
simultaneously more target interaction than targeting only a single cell 
or a single compartment interaction [27].
When the cancer cell is formed and the spheroid state develops 
gradually, the transformed cells will attract feeder cells, forming a new 
tissue structure, in which the polarity and place of cells are disturbed. 
Therefore, the tissue is disordered. The newly formed disordered tissue 
contains the tumor cells supported by the attracted stromal cells. The 
tumor cells are protected and fed by stroma and now have the possibility 
of invading the normal tissue, where tumor stroma functioning as a 
“Trojan horse”.
The normal physiological activities of cells in the region of 
disordered tissue or an entire organ consisting of disordered tissue, will 
present gradients of electric potential that differ from normal ordered 
tissue. In a conventional sense, the movement of fluids that transport 
ions and other necessary materials to reaction sites in the disordered 
tissue, severely compromise colonization of normal tissue by cancer 
cells [9,15]. Others have demonstrated an additional pathway for energy 
exchange that permits reactions among distantly situated regions of the 
colonized tissue [28]. The living cells at the periphery of a tumor act 
as a “semipermeable” sieve or barrier between the surroundings and 
central necrosis in the tumor. This property may at first inspection not 
be quite obvious. The tumors consisting of cancer cells and stromal cells 
make the tissue firmer and denser than the surrounding normal tissues. 
This general firmness and greater density of the tumor serves to identify 
palpable cancers rather readily (breast and prostatic cancers are good 
examples). The sieve functions of various interstitial channels in tumors 
are increased compared to the surrounding normal tissue [15].
The development of stroma begins and is subsequently followed 
by invasion. Hence, the network of interstitial channels in a tumor 
potentially constitutes a relative barrier to interstitial flow, i.e., a “tumor 
barrier”. On both sides of the tumor barrier, non-permeable bodies 
may be found. Many of these biological units may then be too large 
to pass through the intercellular spaces of an organized tissue. In this 
sense the intercellular sieve of a tumor acts as a barrier where material 
can be adsorbed or trapped by diffusion and closed electric transports 
[16]. What is the relationship of the electron deficiencies in cancer that 
result from less than adequate mitochondrial function? Various charge 
transfer cycles (CTC) of primary, secondary or tertiary nature exist in 
biological systems [28]. The electron deficiency is not a generalized 
deficiency, but a very specific one where one CTC cycle is not operating 
or is inactive [28]. Can a deficiency of one or more CTC cycles be 
exploited for inhibiting tumor growth? The answer is definitely no! 
They are responsible for tumor formation.
In general, we think that the direction of tumor growth and 
invasion of surrounding normal tissues is due to mechanism of auto-
phagocytosis or cannibalism (self- and xeno-cannibalisms), defined 
as a superparasitism, is based on the 2nd law of thermodynamics 
[13,18,29]. Consequently, the application of well defined external force 
fields- may reverse the direction of tumor growth by the modification 
of the direction of some particular entropy flow therefore serving to 
modify parasitic interaction. Exposure of the “tumor-normal tissue 
area” to a physical force such as pulsed application of square wave 
electric potential, or, chemical (e.g. specific apoptosis inducers) may 
yield the desired modification of tumor growth. Blocking essential 
local energy producing mechanisms by the inhibition of anaerobic 
glycolysis, inhibition of the beta-oxidation of fatty acids as growth 
stimulators, blocking the alternative pathway of respiration branches 
by the application of SHAM (salicyl-hydroxamic acid) or, by biological 
intervention such as immunomodulation, can be promising ways to 
combat cancer. 
Perspectives in immunology for stroma targeted therapy
The target of tumor killing activity of a low dose alkylating agent- an 
anticancer drug- was dissociated from its immunomodulating activity 
by treating mice bearing a tumor resistant to certain alkylating drugs. 
Induction of specific anti-tumor response by a low dose of alkylating 
drugs was due to expression of "latent anti-tumor" capability [30]. This 
fits the conception that "suppressed concomitant immunity" occurring 
in tumor-bearing animals can be activated. The immunomodulating 
activity of alkylating drugs was related to enhancement of T-cell 
functions by impairment of suppressor T-cell activity, enhancement 
of effector T-cell activity and increased production of cytokines at the 
tumor site. A low dose of anticancer agent had an immunomodulating 
effect in human cancer such as reduction of ConA-induced suppressor 
cell activity in melanoma, some improvement in addition to use of 
melanoma vaccine, and potentiation of DTH in cancer patients. The 
immunomodulating effect of alkylating drugs suggests that their 
use might be beneficial not only for killing tumor cells but also for 
promoting specific anti-tumor immune response [30]. 
The need to modify xenogenization of tumor cells in vivo to 
make the cancer cell more immunogenic and to raise an efficient 
protective immune response was studied in experimental models by 
the use of xenogenized human tumor cells for immunotherapy by using 
chemically and viral modified tumor cells [31]. Modified tumor cells 
were found partially effective as immunomodulating agents. Moreover, 
the mitogenic effects of agents on alveolar fibroblasts suggest a role for 
in fibrogenesis in support of cancer stroma, inasmuch as the supportive 
component of tumor stroma was reduced [32]. 
Some cancer vaccines that have been used in clinical trials 
which have resulted in partial beneficial therapeutic effects have not 
provided a full solution for rational use of thymic humoral factor as 
immunotherapy against cancer [33]. The use of cell free mediators for 
cancer immunotherapy in clinical trials suggests that much remains 
to be done in order to assure effective and reproducible therapeutic 
effectiveness of immunotherapy protocols for routine use in the 
treatment of human cancers [34]. Epstein Barr Virus (EBV) induces 
production of a suppressor factor in the supernatant of B-cell cultures 
[35]. BCG induces in the patient immune processes that target the early 
stages of a urinary bladder cancer. These findings above, collectively 
suggest that both T and B cells play important roles in the immune 
regulation and immune suppression by EBV [36].
Human melanoma cells secrete a factor that inhibits 
phytohemagglutinin induced T- cell proliferation and lipopolysaccharide 
induced B-cell proliferation. It is supposed that these factors have a role 
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in protecting the melanoma tumor from attack by the immune system 
and reduce the antitumor responses of the host [37]. At any rate, antigen 
activated human macrophages have therapeutic activity against human 
tumor cells growing in mice [38]. The regulatory role of inflammatory 
mediators and their relationships with eicosanoids is a network that 
controls the expression of antitumor activity of the macrophages in 
cell to cell contact, and, because production of these anti-tumor factors 
can be shown in the medium containing the tumor and activated 
macrophage, these soluble factors as antitumor immunomodulators 
have potential for immunotherapy of human malignancies [39].
The stromal cells may regulate local immune responses by 
interacting cancer cells with the tumor-infiltrating T lymphocytes 
[40]. In addition, immune competent cells can mediate the cancer to 
accommodate, to adapt to the host and to avoid attack by host immune 
system. Stromal cells affect the immune response; create immune 
tolerance and barriers that avoid host immunity to the cancer cell. 
The tumor tolerizing mechanisms result in the inability of T-cells 
to destroy the tumor cells [41]. Suppression of T-cell activity is an 
important contributing factor by down regulation of MHC molecules, 
resulting in a decreased expression of HLA class I antigens [42], and the 
altered HLA class I phenotypes in human tumors is responsible for the 
immune suppression in cancer. Interestingly, the tumor cells do not only 
inhibit directly immune function, they kill infiltrating antigen specific 
T-lymphocytes [43,44]. However, these studies cannot be extrapolated 
to in vivo effects [45,31-38].
The tumor-shed soluble MHC class I homologues MICA and 
B are often produced by epithelial tumors resulting in the reduced 
responsiveness of tumor specific natural killer T cells [43,44]. In 
addition the tumor cells express T- cell stimulating antigens that are 
tolerated by the T-cells leading to insufficient antigen density [41,45,46]. 
Due to immune deficiencies in the host and immune tolerance 
of cancer cells, the tumor develops as a stealth object in the body by 
several mechanisms such as a tumor virus blocking the MHC1 antigen 
transport to the surface of the cells [47]. Consequently the cytotoxic 
immune response cannot eliminate the tumor cells. The production 
of a great variety of immunosuppressive factors involves complex 
mechanisms that contribute to the stealth behavior of cancer in the 
organism. Tumor gradually grows and invades the healthy tissues 
without early presentation of symptoms. Due to immunosuppression 
induced by human tumors, the tumor escapes immune surveillance and 
continues to grow [48].
As a by-product of oxidative phosphorylation Reactive Oxygen 
Species (ROS) are formed that may contribute to tumor initiation 
or progression [51]. Apart from damaging effects on nuclear and 
mitochondrial DNA, they are able to directly activate cell signaling such 
as MAP kinase, or phosphoinositide 3-kinase pathways [52], and they 
are implicated in the myc-induced tumorigenesis [53]. The hypoxia-
inducible factor (HIF) seems to be a particularly important factor 
in the ROS-mediated tumorigenesis. HIF is known to mediate the 
upregulation of glycolytic genes and a global shift in cellular metabolism 
toward glycolysis, and the ROS stabilize and activate this factor under 
hypoxic conditions [54]. Therefore it is not surprising the targeting of 
mitochondrial ROS in cancer therapy is a novel approach. The tempting 
idea that large doses of antioxidants might interfere with the tumor 
development or progression proved to be inconsistent and controversial 
in human studies, still there are data about the ROS-mediated cell 
killing by different cytostatic drugs [55], or there is ongoing research to 
find selective anticancer compounds [56]. Similarly, targeted inhibition 
of HIF is also under investigation [57].
The redox-status in cancer stem cells is hardly understood. These cells 
are believed to be relatively radio-resistant and drug resistant because of 
low ROS-level and high concentration of scavenger molecules. Redox-
modulating strategies could serve again new therapeutic approaches to 
overcome drug resistance. However, breaking their redox-adaptation 
has a Janus-face [58]. Nevertheless, some promising results are available 
indicating the selective killing effect of a thiol-depleting compound on 
leukemic stem cells without significant toxicity of normal hemopoetic 
cells [59]. 
Apparently the stroma has a key role in tumor development, 
consequently can be considered as possible target of therapy. There 
are opportunities in at least two different areas of therapy: a. focused 
on tumor stroma the modification cancer cell adhesion, proteolysis, 
extracellular matrix and various signal pathways as was suggested 
by Liotta et al. in 2002 [17]. Other opportunities are related to 
thermodynamics or physics. We had quantitively demonstrated that 
entropy production of rates of cancer cells is always higher than that 
of normal cells Molnar et al [60].When an electric field is applied to 
cells the entropy production rate of normal cells may exceed that of 
cancer cells [59]. The thermodynamical approaches as confirmed 
by calculations of the effects of external energy of electric field as the 
application of physical on the growth inhibition of cancer cells was a 
promising intervention as suggested by Luo et al. [29].
The electric effect of field was demonstrated recently in vivo where 
high electric fields induced the ablation of cancer in various metastatic 
tumors in mice and in clinical trials due to electric ablation in changes 
occurred in the tumor microenvironment. The induction of antitumor 
immunity was also involved in the complex effects of the pulsed electric 
forces [61].
Conclusion
Due to the large number of distinct cancer cell types and subsequent 
departure from their appearance, functions, biochemical properties and 
energy and nutritional needs when they metastasize to different parts of 
the body that exhibit different stromal conditions, it is highly doubtful 
that any single form of therapy that specifically aims at one target, will 
Cancer cannibalism is an important mechanism of malignancy 
responsible for immunotolerance or resistance when metastatic tumor 
use cannibalism at low nutrient supply, The cannibal cells feed on 
sibling tumor cells and other cells under acidic environment that allow 
activation of lytic enzymes such as cathepsin B, and other factors as 
caveolin and actin-linker molecule ezrin. Various steps of cannibalisms 
may be explored and exploited for anti-stromal therapy [3,17,20,21,49]. 
From thermodynamic aspects the toxic effects of entropy flow from 
tumor to normal tissue plays an important role in the superparasitism, 
in the competitive exclusion between tumor and normal host cells 
where the possible targets are the proteolysis, extracellular matrix, 
various signal pathways, VEGF etc. [3,50]. Tumor gradually grows and 
invades the healthy tissues without early presentation of symptoms. 
Due to immunosuppression induced by human tumors, the tumor 
escapes immune surveillance and continues to grow [48].
Therapeutic opportunities that exploit various facets of cancer 
development, invasion, and the role that the stroma and its distinct 
composition of cell types play [17], are briefly summarized in Table 1. 
The in situ ablation of solid tumors by electric forces and effects on the 
tumor microenvironment and antitumor immunity has been discussed 
by others and suggestions for therapy well presented [61]. 
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be effective against many cancer cell types. These differences may not 
be as limiting as one may think. Rather they may present the ability to 
selectively target the sensitive target of a distinct cancer cell type. This in 
turn may result in far less damage to normal cells as is the case with the 
“shot-gun approaches” of chemotherapy and radiotherapy in use today.
References
1. Alva AS, Gultekin SH, Baehrecke EH (2004) Autophagy in human tumors: cell 
survival or death? Cell Death Differ 11: 1046-1048.
2. Kojima S, Sekine H, Fukui I, Ohshima H (l998) Clinical significance of 
cannibalism in urinary cytology of bladder cancer. J Acta Cytologica 42: 1365-
1369. 
3. Molnar J, Varga ZG, Thornton-Benko E, Thornton B (2011) The second Law of 
Thermodynamics and Host–Tumor Relationships: Concepts and opportunities. 
Application of Thermodynamics to Biological and Material Science Edited by 
Tadashi Mizutani (ISBN 978-953-980-6).
5. Cavelier G (2000) Theory of malignant cell transformation by superoxide 
fate coupled with cytoskeletal electron-transport and electron-transfer. Med 
Hypotheses 54: 95-98.
6. WARBURG O (1956) On the origin of cancer cells. Science 123: 309-314.
7. Wang F, Ogasawara MA, Huang P (2010) Small mitochondria-targeting 
molecules as anti-cancer agents. Mol Aspects Med 31: 75-92.
8. Fröhlich H (1980) The biological effects of microwaves and related questions. 
Advances in Electronics and Electron Physics 53: 85. 
10. Chen N, Schoenbach KH, Kolb JF, James Swanson R, Garner AL, et al. (2004) 
Leukemic cell intracellular responses to nanosecond electric fields. Biochem 
Biophys Res Commun 317: 421-427.
11. Barsamian ST, Barsamian SP (1988) Dielectric investigation of murine cancer 
cells. J of Biological Physics 16: 25-30. 
12. Yoo DS (2004) The dielectric properties of cancerous tissues in a nude mouse 
xenograft model. Bioelectromagnetics 25: 492-497.
13. Molnar J, Liao-fu L, Gyemant N, Mucsi I, Vezendi K, et al. (2007) Cancer growth 
is superparasitism in host: a Predator-Prey Relationship Acta Scientiarum 
Naturalium Universitas NeiMongol 38: 44-63. 
14. Varro A, Holmberg C, Quante M, Steele I, Kumar J, et al. (2012) Release of 
TGFssig-h3 by gastric myofibroblasts slows tumor growth and is decreased 
with cancer progression. Carcinogenesis. [Epub ahead of print] 
15. Nordenström BEW (1989) Biologically Closed Electric Circuits. Nordic Medical 
Publications: 122-124.
16. Nordenström BEW (1989) Biologically Closed Electric Circuits, Clinical, 
Experimental and Theoretical Evidence for an Additional Circulatory System. 
Nordic Medical Publications: 148. 
17. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. 
Nature 411: 375-379.
18. Molnar J, Thornton BS, Thornton-Benko E, Amaral L, Schelz Zs, et al. (2009) 
Thermodynamics and Electrobiologic properties for therapies to intervene in 
cancer progression, Current Cancer Therapy Reviews 5: 158-169. 
21. Ohkoshi M, Sasaki Y (2005) Antimetastatic activity of a synthetic serine 
protease inhibitor, FOY-305 (Foypan). In vivo 19: 133-136.
23. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R (2011) Interaction of 
tumor cells with the microenvironment. Cell Commun Signal 9: 18.
24. Watchorn TM, Waddell I, Dowidar N, Ross JA (2001) Proteolysis-inducing factor 
regulates hepatic gene expression via the transcription factors NF-(kappa)B 
and STAT3. FASEB J 15: 562-564.
25. Islam-Ali BS, Tisdale MJ (2001) Effect of a tumour-produced lipid-mobilizing 
factor on protein synthesis and degradation. Br J Cancer 84: 1648-1655.
26. Tisdale MJ (2003) Pathogenesis of cancer cachexia. J Support Oncol 1: 159-
168.
27. Zalatnai A (2006) Molecular aspects of stromal-parenchymal interactions in 
malignant neoplasms. Curr Mol Med 6: 685-693. 
28. Guttmann F, Johnson C, Keyzer H, Molnar J (1997) Charge transfer complexes 
in biological systems, Marcel Dekker Inc., New York Basel Hong Kong 1997. 
29. Liao-fu L, Molnar J, Ding H, Lv X, Spengler G (2006) Attempts to introduce 
thermodynamics in anticancer therapy using entropy production difference 
between cancer and normal cells. Acta Scientiarum Naturalium Universitatis 
Nei Mongol 37: 295-303. 
30. Ben-Efraim S (2001) Immunomodulating anticancer alkylating drugs: targets 
and mechanisms of activity. Curr Drug Targets 2: 197-212.
31. Ben-Efraim S, Bizzini B, Relyveld EH (2000) Use of xenogenized (modified) 
tumor cells for treatment in experimental tumor and in human neoplasia. 
Biomed Pharmacother 54: 268-273.
32. Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, et al. (1999) Effect of 
endothelin-1 on alpha-smooth muscle actin expression and on alveolar 
fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 21: 
759-775.
33. Ben-Efraim S, Keisari Y, Ophir R, Pecht M, Trainin N, et al. (1999) 
Immunopotentiating and immunotherapeutic effects of thymic hormones and 
factors with special emphasis on thymic humoral factor THF-gamma2. Crit Rev 
Immunol 19: 261-284.
34. Ben-Efraim S (1999) One hundred years of cancer immunotherapy: a critical 
appraisal. Tumour Biol 20: 1-24.
35. Drucker I, Ben-Efraim S, Klajman A (1996) Secretion of suppressor factors by 
EBV infected B cell lines. Anticancer Res 16: 2857-2861.
36. Ben-Efraim S (1996) Cancer immunotherapy: hopes and pitfalls: a review. 
Anticancer Res 16: 3235-3240.
37. Giacomoni D, Ben-Efraim S, Najmabadi F, Dray S (1990) Inhibitors of 
lymphocyte activation secreted by human melanoma cell lines. Med Oncol 
Tumor Pharmacother 7: 273-280.
38. Ben-Efraim S, Tak C, Romijn JC, Fieren MJ, Bonta IL (1994) Therapeutical 
effect of activated human macrophages on a human tumor line growing in nude 
mice. Med Oncol 11: 7-12.
39. Bonta IL, Ben-Efraim S (1993) Involvement of inflammatory mediators in 
macrophage antitumor activity. J Leukoc Biol 54: 613-626.
41. Restifo NP (2001) Hierarchy, Tolerance and Dominance in the Antitumor T-cell 
Response. J Immunother 24: 193-194. 
Target Example agent Comments
Adhesion Vitaxin (anti-acfl3-mAb)
Cytostasis in patients, 
antitumor and anti-
angiogenic in animal 
models
Proteolysis Matrix metalloproteinase inhibitors
Cytostatic in patients
Stromal fibrosis






Selective to endothelial 
cells
Active in animal models
Active in combinations 
in vitro
Table 1:  Examples for therapeutics targeting stroma-tumor interactions [17].
4. Goldblatt H, Cameron G (1953) Induced malignancy in cells from rat 
myocardium subjected to intermittent anaerobiosis during long propagation in 
vitro. J Exp Med 97: 525-552.
9. Thornton BS (1984) Inversion of Raman spectra of living cells indicates 
dielectric structure related to energy control. Physics Letters 106: 198-202. 
19. Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin 
Oncol 28: 36-41.
20. Engi H, Gyémánt N, Ohkoshi M, Amaral L, Molnár J (2009) Modelling of tumor-
host coexistence in vitro in the presence of serine protease inhibitors. In vivo 
23: 711-716. 
22. Rasanen K, Vaheri A (2010) Activation of fibroblasts in cancer stroma. Exp Cell 
Res 316: 2713-2722.
40. Gorgun G, Anderson KC (2011) Intrinsic modulation of lymphocyte function by 
stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy 
3: 1253-1264.
Citation: Molnár J, Mucsi I, Engi H, Spengler G, Amaral L, et al. (2013) The Role of Stroma in Tumour-Host Co-Existence: Some Perspectives in 
Stroma-Targeted Therapy of Cancer. Biochem Pharmacol 2:107. doi:10.4172/2167-0501.1000107
Page 6 of 6
Volume 2 • Issue 1 • 1000107
Biochem Pharmacol
ISSN:2167-0501 BCPC, an open access journal 
42. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, et al. 
(1997) Implications for immunosurveillance of altered HLA class I phenotypes 
in human tumors. Immunol Today 18: 89-95. 
43. Bergmann-Leitner ES, Duncan EH, Leitner WW (2003) Identification and 
targeting of tumor escape mechanisms: a new hope for cancer therapy? Curr 
Pharm Des 9: 2009-2023.
44. M, O’Connel J, O’Sulivan GC, Brady C, Roche D, et al. (1998) The Fas 
counterattack in vivo: apoptotic depletion of tumor infiltrating lymphocytes 
associated wih Fas ligand expression by human esophageal carcinoma. J 
Immunology 160: 5669-5675. 
45. Restifo NP (2000) Not so Fas: Re-evaluating the mechanisms of immune 
privilege and tumor escape. Nat Med 6: 493-495.
46. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands 
impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
47. Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression 
induced by human tumors. Cancer Immunol Immunother 46: 175-184.
48. Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune 
surveillance. Adv Cancer Res 83: 117-158.
49. Fais S (2007) Cannibalism: a way to feed on metastatic tumors. Cancer Lett 
258: 155-164.
50. Peng Y, Jia XC, Liaofu L, Molnar J, Spengler G, et al. (2005) A theoretical model 
of cancerous and normal cells growth affected by entropy flow. In: Proceedings 
of International Seminar on Drug Resistance in cancer, Szeged, December 5: 
10-14. 
51. Fogg VC, Lanning NJ, Mackeigan JP (2011) Mitochondria in cancer: at the 
crossroads of life and death. Chin J Cancer 30: 526-539.
52. Weinberg F, Chandel NS (2009) Reactive oxygen species-dependent signaling 
regulates cancer. Cell Mol Life Sci 66: 3663-3673.
53. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, et al. (2002) c-Myc can induce 
DNA damage, increase reactive oxygen species, and mitigate p53 function: a 
mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
54. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, et al. (2005) Mitochondrial 
dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing 
and hypoxic HIF-alpha activation. Cell Metab 1: 393-399.
55. Gogvadze V, Orrenius S, Zhivotovsky B (2009) Mitochondria as targets for 
cancer chemotherapy. Semin Cancer Biol 19: 57-66.
56. Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer 
therapy. Nat Rev Drug Discov 9: 447-464.
57. Wenger JB, Chun SY, Dang DT, Luesch H, Dang LH (2011) Combination 
therapy targeting cancer metabolism. Med Hypoth 76: 169-172. 
58. Acharya A, Das I, Chandhok D, Saha T (2010) Redox regulation in cancer: a 
double-edged sword with therapeutic potential. Oxid Med Cell Longev 3: 23-34.
59. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, et al. (2007) Rapid and 
selective death of leukemia stem and progenitor cells induced by the compound 
4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 110: 4436-
4444.
60. Molnar J, Thornton BS, Molnar A, Gaal D, Luo L, et al. (2005) Thermodynamic 
aspects of cancer: possible role of negative entropy in tumor growth, its relation 
to kinetic and genetic resistence. Letters in Drug Design and Discovery 2: 429-
438. 
61. Keisari Y, Korenstein R (2013) In situ ablation of solid tumors by electric forces 
and its effect on the tumor microenvironment and anti-tumor immunity. Tumor 
Ablation The Tumor Microenvironment 5: 133-153.
















Citation: Molnár J, Mucsi I, Engi H, Spengler G, Amaral L, et al. (2013) The 
Role of Stroma in Tumour-Host Co-Existence: Some Perspectives in Stroma-
Targeted Therapy of Cancer. Biochem Pharmacol 2:107. doi:10.4172/2167-
0501.1000107
